Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression
Top Cited Papers
- 1 February 2016
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (1) , 77-81
- https://doi.org/10.1097/jcp.0000000000000436
Abstract
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.Keywords
This publication has 22 references indexed in Scilit:
- Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary reportRevista Brasileira de Psiquiatria, 2015
- Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case reportInternational Journal of Bipolar Disorders, 2015
- The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjectsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Reduced Caudate and Nucleus Accumbens Response to Rewards in Unmedicated Individuals With Major Depressive DisorderAmerican Journal of Psychiatry, 2009
- The Subgenual Anterior Cingulate Cortex in Mood DisordersCNS Spectrums, 2008
- Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriantPsychopharmacology, 2006
- Reliability and validity of a Portuguese version of the Young Mania Rating ScaleBrazilian Journal of Medical and Biological Research, 2005
- Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and PharmacokineticsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Factor structure of Bech's version of the Brief Psychiatric Rating Scale in Brazilian patientsBrazilian Journal of Medical and Biological Research, 2002
- Confiabilidade da "Entrevista Clínica Estruturada para o DSM-IV - Versão Clínica" traduzida para o portuguêsRevista Brasileira de Psiquiatria, 2001